Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Cryopreservation Equipment Market - Insights

Cryopreservation is a process of maintaining biological samples in a form of suspended state at cryogenic temperature for considerable period and is used to preserve the fine structure of cells. Through this process, samples of cells, tissues, and organelles are cooled at very low temperatures (less than -2130F), for preservation. Cryopreservation is primarily used in the preservation of oocytes and embryos with in-vitro fertilization (IVF) cycle, prior to chemotherapy for women diagnosed with breast cancer, in order to preserve their reproductive capacity. Moreover, frozen embryos are found to provide similar results as fresh embryos. For instance, according to the Assisted Reproductive Technology in Australia and New Zealand 2013 report published by UNSW's National Perinatal Epidemiology and Statistics Unit (NPESU), over 25% increase has been recorded in the birth rate associated with frozen embryo transfers over the last five years, rising from 18% to 23%. Additionally, IVF treatments using frozen embryos increased from 39% of IVF cycles in 2009 to 45% of cycles in 2013. Linde LLC introduced its new CRYOLINE CWI CRYOWAVE impingement freezer at the International Production & Processing Expo (IPPE) in Atlanta, in January 2018. Company’s new product combines the benefits of CRYOWAVE product agitation with cryogenic gas impingement flows, which utilizes liquid nitrogen to freeze products.

The global cryopreservation equipment market is estimated to be valued at US$ 4,318.1 million in 2017 and is expected to witness a CAGR of 13.2% over the forecast period (2017–2025)

Figure 1. Global Cryopreservation Equipment Market Share (%), by Region, 2017

Source: Coherent Market Insights Analysis (2017)

Increasing number of government initiatives for preservation of stem cells is expected to augment market growth

New York Blood Center (NYBC) initiated the National Cord Blood Program, in 1992, to investigate, collect, process, freeze, and store the cord blood cells in liquid nitrogen freezers, which are used when patients with hematopoietic transplants are unable to find compatible bone marrow donors. NCBP is the first and largest cord bank in the world, which recorded a collection of over 60,000 cord blood units, till 2016. NCBP has provided cord blood units for transplantation to over 4,900 recipients, throughout the world. Additionally, in 2011, Canada’s Ministry of Health, initiates Canada’s first national, publicly funded umbilical cord blood bank, which aims to provide the donations for the allogeneic hematopoietic stem cell transplant.

North America market accounted for the largest market share, followed by Europe in 2016. This is owing to the major collaboration and agreement of key players in the cryopreservation equipment manufacturing. In June 2016, Cryogenic Control made a distribution agreement with Paramount Gas Products and Cryo Inc. According to this agreement, Paramount Gas Products and Cryo Inc. will become the official distributors of Cryogenic Control’s first product, ELLN2 in North America. The agreement allows the Paramount Gas Products and Cryo Inc. to distribute the ELLN2 in certain major states of North America.

The continued stem cell research studies are found to be highest among the Asian countries. For instance, according to the report jointly prepared by Elesevier, EuroStemCell and Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS), in 2013, and discussed in the World Stem Cell Summit-2013, Singapore and Japan have the highest activity in stem cell research while China is top contributor in terms of volume by publishing the stem cell research studies. In addition, the stem cell research is growing at faster rate (7%) compare to the world average growth in research (2.9%). Moreover, the stem cells are used to produce the regenerative medicine and stem cell based therapeutics and drugs. The growing stem cell research will eventually fuel the demand for cryopreservation equipment and thereby fueling the cryopreservation equipment market in coming years.

Besides, cryopreservation of gametes and embryos are the important aspects of Assisted Reproductive Technology (ART) and in-vitro fertilization (IVF) treatments. According to the data published in the Oxford University Press (OUP) in November 2016, cryopreserved embryo transfer cycles is growing in the Europe. The cryopreserved cycles are contributed to 32% of the transfers in 2011 compared to the 28% in 2010. Some countries in Europe such as Switzerland, Finland, Netherlands, Sweden, and Iceland, recorded the proportion of cryopreserved embryo transfer as higher than 50%, in 2011.

The U.K. Stem Cell Bank, funded by Medical Research Council, U.K. and Biotechnology and Biological Sciences Research Council, provides quality controlled, ethically approved, assured repository of human embryonic, and fetal and adult stem cell lines for research and healthcare developments. The U.K. Stem Cell Line Registry lists the human embryonic stem cells, which are approved to be used in the U.K. Moreover, in February 2017, U.K. Stem Cell Bank (UKSCB) distributed the human cell lines developed at the University of Sheffield for use in medical therapies and research.

Some of the key players operating in the global cryopreservation equipment market are Thermo Fisher Scientific, Inc., Custom Biogenic Systems, Chart Biomedical Co. Ltd., Merck KGaA, Barber-Nichols Inc., Praxair Technology, Inc., Linde LLC, Planer PLC, Cryologic Pty. Ltd., Charter Medicals, Nikkiso Cryo Inc., Cryogenic Control, and Haimen United Laboratory Equipment Development Co., Ltd.